- Home
- MRSN vs INVE Comparison
MRSN vs INVE Comparison
Compare MRSN & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- INVE
- Stock Information
- Founded
- MRSN 2001
- INVE 1990
- Country
- MRSN United States
- INVE United States
- Employees
- MRSN N/A
- INVE N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- MRSN Health Care
- INVE Technology
- Exchange
- MRSN Nasdaq
- INVE Nasdaq
- Market Cap
- MRSN 71.9M
- INVE 82.2M
- IPO Year
- MRSN 2017
- INVE 1997
- Fundamental
- Price
- MRSN $0.33
- INVE $3.20
- Analyst Decision
- MRSN Buy
- INVE Strong Buy
- Analyst Count
- MRSN 3
- INVE 3
- Target Price
- MRSN $4.00
- INVE $6.83
- AVG Volume (30 Days)
- MRSN 3.0M
- INVE 82.8K
- Earning Date
- MRSN 03-03-2025
- INVE 03-05-2025
- Dividend Yield
- MRSN N/A
- INVE N/A
- EPS Growth
- MRSN N/A
- INVE N/A
- EPS
- MRSN N/A
- INVE 3.14
- Revenue
- MRSN $40,497,000.00
- INVE $26,628,000.00
- Revenue This Year
- MRSN N/A
- INVE N/A
- Revenue Next Year
- MRSN N/A
- INVE $40.32
- P/E Ratio
- MRSN N/A
- INVE $1.02
- Revenue Growth
- MRSN 9.88
- INVE N/A
- 52 Week Low
- MRSN $0.33
- INVE $2.95
- 52 Week High
- MRSN $4.64
- INVE $8.52
- Technical
- Relative Strength Index (RSI)
- MRSN 28.30
- INVE 43.06
- Support Level
- MRSN $0.41
- INVE $3.03
- Resistance Level
- MRSN $0.42
- INVE $3.39
- Average True Range (ATR)
- MRSN 0.04
- INVE 0.17
- MACD
- MRSN -0.00
- INVE -0.01
- Stochastic Oscillator
- MRSN 2.39
- INVE 35.42
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.